Abstract
Technetium-99m exametazime (99mTc-d,l-HMPAO), prepared by the reconstitution of the Ceretec kit, is widely used in the investigation of regional cerebral blood flow. The radiochemical purity specification of not less than 80% lipophilic complex requires that the kit is used within 30 min of reconstitution In certain circumstances this imposes restrictions on its clinical availability. A number of approaches to extending the 30-min shelf life have been proposed and these are discussed. A method of stabilising the kit by the addition of 200 μg cobalt chloride hexahydrate (CoCl2 · 6H2O) in 2 ml of water is described. The addition of this solution can extend the shelf life of the reconstituted kit to at least 5 h post reconstitution.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bayne VJ, Forster AM, Tyrrell DA. Use of sodium iodide to overcome the eluate age restriction for Ceretec reconstitution. Nucl Med Commun 1989;10:29–33.
Millar AM. A routine method for using sodium iodide to stabilize sodium pertechnetate [99Tcm] dispensed for the preparation of 99Tcm-exametazime. Nucl Med Commun 1992;13: 306–311.
Reymen M, Verwimp H, Van Nerom C, Bormans G, De Roo M, Verbruggen A. Critical evaluation of stabilization methods for 99m-Tc-d,I-HM-PAO. Eur J Nucl Med 1991;18: 532.
Hung JC, Corlija M, Volkert WA, Holmes RA. Kinetic analysis of technetium-99m d,I-HM-PAO decomposition in aqueous media. J Nucl Med 1988;29:1568–1576.
Hung JC, Volkert WA, Holmes RA. Stabilization of technetium-99m-d,l-hexamethylpropyleneamine oxime (99mTc-d,l-HMPAO) using gentisic acid. Int J Radiat Appl Instrum [B] 1989;16:675–680.
Lang J, Barbarics E, Lazar J, Janoki GA, Papos M, Csernay L. Effects of labeling conditions and formulation of kit on in vitro stability of 99mTc-d,I-HM-PAO. Eur J Nucl Med 1989;15:424.
Lang J, Barbarics E, Lazar J, Janoki GA, Papos M, Pavics L, Csernay L. A novel d,l-HM-PAO kit formulation providing high in vitro lipophilic complex stability. Eur J Nucl Med 1990;16:541.
Billinghurst MW, Abrams DN, Lawson MS. Stabilization of [99m-Tc]HMPAO - 1. Ethanolic preparation. Int J Radiat Appl Instrum [A] 1991;42:607–612.
Ballinger JR, Gulenchyn KY. Alternative formulations of technetium-99m HMPAO. Int J Radiat Appl Instrum [A] 1991;42:315–316.
Sampson CB, Solanki C. Stabilisation of Tc-99m exametazime using ethanol and storage at a low temperature. Eur J Nucl Med 1991;18: 532.
Solanki KK. Radiopharmaceutical compositions. UK Patent Application GB 2 231 267 A, 1990.
Goff H, Kidwell S, Lauher J, Murmann RK. Kinetic and thermodynamic studies on a labile traps-dinitrocobalt(III) complex. Inorg Chem 1973;12:2631–2640.
Diomedi-Camassei F, Nocchi E, Sartori G, Adamson AW. Photochemistry of macrocyclic coordination compounds I. A cobalt(III) complex containing a tetradentate equatorial ligand PnAO. Inorg Chem 1975;14:25–33.
Berger R. Radical scavengers and the stability of 99m-Tc-radio-pharmaceuticals. Int J Radiat Appl Instrum [B] 1982; 33:1341–1344.
Author information
Authors and Affiliations
Additional information
Correspondence to: P.S. Weisner
Rights and permissions
About this article
Cite this article
Weisner, P.S., Bower, G.R., Dollimore, L.A. et al. A method for stabilising technetium-99m exametazime prepared from a commercial kit. Eur J Nucl Med 20, 661–666 (1993). https://doi.org/10.1007/BF00181755
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00181755